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Edited by Amy McGoughAbstract Cyclic nucleotides acting through their associated
protein kinases, the cGMP- and cAMP-dependent protein
kinases, can relax smooth muscles without a change in free
intracellular calcium concentration ([Ca2þ]i), a phenomenon
referred to as Ca2þ desensitization. The molecular mechanisms
by which these kinases bring about Ca2þ desensitization are
unknown and an understanding of this phenomenon may lead to
better therapies for treating diseases involving defects in the
contractile response of smooth muscles such as hypertension,
bronchospasm, sexual dysfunction, gastrointestinal disorders and
glaucoma. Utilizing a combination of real-time proteomics and
smooth muscle physiology, we characterized a distinct subset of
protein targets for cGMP-dependent protein kinase in smooth
muscle. Among those phosphoproteins identiﬁed was calponin
homology-associated smooth muscle (CHASM), a novel protein
that contains a calponin homology domain and shares sequence
similarity with the smoothelin family of smooth muscle speciﬁc
proteins. Recombinant CHASM was found to evoke relaxation
in a concentration dependent manner when added to permeabi-
lized smooth muscle. A co-sedimentation assay with actin
demonstrated that CHASM does not possess actin binding
activity. Our ﬁndings indicate that CHASM is a novel member
of the smoothelin protein family that elicits Ca2þ desensitization
in smooth muscle.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.1. Introduction
Smooth muscle relaxation occurs through one of the two
mechanisms: passive relaxation following the removal of the
contractile stimulus or active relaxation induced by the acti-
vation of cyclic nucleotide-dependent protein kinases in the* Corresponding author. Fax: +1-919-668-0977.
E-mail address: hayst001@mc.duke.edu (T.A.J. Haystead).
1 These authors contributed equally to this work.
2 Present address: Department of Biochemistry and Molecular Biol-
ogy, The Smooth Muscle Research Group, University of Calgary,
Calgary, Alta., Canada T2N 4N1.
Abbreviations: CaMKII, calcium/calmodulin-dependent protein kinase
II; CHASM, calponin homology-associated smooth muscle protein;
NO, nitric oxide; cGMP, guanosine 30,50-cyclic monophosphate; PKG,
cGMP-dependent protein kinase; 8Br-cGMP, 8-bromoguanosine 30,50-
cyclic monophosphate; SMPP-1M, myosin phosphatase; [Ca2þ]i,
intracellular calcium concentration
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doi:10.1016/j.febslet.2004.08.002lasting presence of the contractile stimulus [1–3]. Nitric oxide
(NO), which has been implicated in the regulation of smooth
muscle tone, signals through multiple mechanisms including
stimulation of guanosine 30,50-cyclic monophosphate (cGMP)
synthesis. Increases in intracellular [cGMP] (or [cAMP]) by
cyclic-nucleotide elevating agents lead to the relaxation of in-
tact smooth muscle [1].
One potential mechanism of cGMP-mediated smooth mus-
cle relaxation is through a decrease in intracellular calcium
concentration ([Ca2þ]i) [4,5]. cGMP-dependent protein kinase
(PKG) is an important eﬀector for transducing cGMP signals
into biological responses [6,7]. Several possible cyclic nucleo-
tide-dependent protein kinase substrates have been identiﬁed
including: the inositol 1,4,5-triphosphate (IP3) receptor, IP3-
associated cGMP kinase substrate (IRAG), phospholamban,
the large conductance calcium-activated potassium channels
(BKCa), and the plasma membrane Ca
2þ-pump. Phosphory-
lation of the IP3 receptor is believed to inhibit IP3-induced
Ca2þ release [8]. Similarly, phosphorylation of IRAG is asso-
ciated with an inhibition of IP3-dependent Ca
2þ release [9].
Phosphorylation of phospholamban causes activation of the
Ca2þ-ATPase in the sarcoplasmic reticulum thereby decreasing
[Ca2þ]i [10]. Stimulation of PKG produces membrane polari-
zation and subsequent vasodilation through BKCa channel
activation by channel phosphorylation [11]. Phosphorylation
of the plasma membrane Ca2þ pump increases the aﬃnity of
the pump for Ca2þ [12] and promotes extrusion of Ca2þ into
the extracellular space. These cyclic-nucleotide-dependent
protein kinase substrates all mediate smooth muscle relaxation
by decreasing [Ca2þ]i. However, cyclic nucleotides acting
through their associated kinases can relax permeabilized
smooth muscle without a comparable change in [Ca2þ]i [5,13–
17]. This phenomenon, whereby a decrease in myosin regula-
tory light chain (RLC) phosphorylation and force occurs
without a proportionate decline in [Ca2þ]i, is referred to as
Ca2þ desensitization [18–20].
Inhibition of MLCK activity has been proposed as one
mechanism of Ca2þ desensitization as cyclic nucleotide-in-
duced phosphorylation of MLCK reduces the activity of
MLCK in vitro. However, inhibitory phosphorylation of
MLCK in vivo appears to be primarily due to CaMKII. An
additional mechanism of Ca2þ desensitization is thought to
involve the activation of smooth muscle myosin phosphatase
(SMPP-1M). Reports have demonstrated that cGMP admin-
istration can accelerate dephosphorylation of RLC when
MLCK activity is inhibited [16,17]. The mechanism of cyclic
nucleotide-dependent activation of SMPP-1M may involveation of European Biochemical Societies.
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unit of SMPP-1M. Evidence for a direct interaction between
SMPP1-1M and PKG has been presented [21,22]. In these
studies, PKG-Ia was targeted to SMPP-1M through a leucine
zipper interaction with MYPT1, and disruption of the PKG-
Ia/SMPP-1M interaction inhibited cGMP-mediated dephos-
phorylation of myosin RLC. However, other investigations
have demonstrated that direct phosphorylation of MYPT1 by
PKG does not appear to alter the enzyme’s activity in vitro
[23,24]. The observation that cGMP causes Ca2þ desensitiza-
tion in smooth muscle through activation of myosin phos-
phatase activity [16,17] therefore suggests an indirect
mechanism involving a mediator protein(s). Previous studies
have identiﬁed multiple proteins that are phosphorylated
during cGMP-induced Ca2þ desensitization, including telokin
[16], and the 20 kDa heat shock-related protein (HSP20) [25];
however, a direct eﬀect on myosin phosphatase activity has yet
to be demonstrated for these proteins. The objectives of the
present study were to identify any additional smooth muscle
proteins that were phosphorylated during cGMP-dependent
relaxation and to evaluate their role in smooth muscle Ca2þ
desensitization.2. Materials and methods
2.1. Materials
CaMKII was provided by Dr. Anthony Means (Duke University).
Smooth muscle MLCK was puriﬁed using a previously established
protocol [26]. Sequencing grade trypsin was from Promega (Madison,
WI). Staphylococcus aureus a-toxin was from List Biological Labora-
tories (Campbell, CA). Precission ProteaseTM was from Amersham
Biosciences (Piscataway, NJ). PKA catalytic subunit, PKG-Ia, and 8-
Br-cGMP were from Calbiochem (San Diego, CA). Microcystin was
obtained from Alexis Biochemicals (San Diego, CA). b-escin was from
Sigma (St. Louis, MO). Recombinant p42MAPK was puriﬁed from
Escherichia coli BL21(DE3)[pET-MK] [27]. Constitutively active
S218D/S222D MEK1 was a gift from Dr. Andrew Cattling (University
of Virginia).
2.2. Two-dimensional gel electrophoresis
For two-dimensional gel electrophoresis, radio-labeled ileum sam-
ples (see below) were homogenized in glass on glass homogenizers in
sample buﬀer containing 5 M urea, 4% CHAPS, 1 mM DTT, and 10
nM microcystin and centrifuged at 15 000 g for 15 min. The super-
natant was removed for two-dimensional gel analysis. Proteins were
visualized with silver staining and gels were dried and subjected to
autoradiography. Spots of interest were excised from the gels and
processed for mass spectrometric analysis.
2.3. Real-time identiﬁcation of phosphoproteins in smooth muscle by
mass spectrometric analysis
Rabbit ileum longitudinal smooth muscle was removed from rabbits
anesthetized by halothane and exsanguinated according to approved
animal protocols. Sheets of ileum smooth muscle (1 cm 0.5 cm)
were permeabilized with S. aureus a-toxin (20 lg/ml) for 40 min at
room temperature in calcium-free solution containing 1 mM EGTA
(G1). Following permeabilization, muscle sheets were washed in Ca2þ-
free solution and contracted with submaximal calcium (pCa6.3). After
10 min, muscle sheets were washed in 10 mM EGTA solution con-
taining 0.5 mM ATP (G10
0
) and then incubated in the same solution
with [c-32P]ATP (1 mCi/sheet) for 5 min. Muscles were then stimulated
with either vehicle (water) or 8-Br-cGMP (100 lM). Muscles were snap
frozen in liquid nitrogen and prepared for two-dimensional gel elec-
trophoresis, as above. Proteins exhibiting increased phosphorylation in
response to 8-Br-cGMP stimulation were cut from the gels and in-gel
digested with trypsin [28]. Extracted tryptic peptides were puriﬁed with
Poros R2 (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions (http://protana.com). The peptides wereconcentrated in a nano-electrospray capillary and placed in the source
head of a QSTAR Pulsar hybrid mass spectrometer (Applied Biosys-
tems) to derive de novo peptide sequences. Peptide sequences were
searched against protein and DNA non-redundant databases using the
FASTS algorithm [29].
2.4. Expression and puriﬁcation of recombinant CHASM
Recombinant CHASM was produced from I.M.A.G.E. cDNA clone
3593616 (Research Genetics). The open reading frame was ampliﬁed
by polymerase chain reaction (PCR) using the 50 primer, CGCGGA-
TCCATGGAGCAGACAG-30 and the 30 primer, GTGCTCGAGT-
GCGGCCGCCC-30. The resultant PCR product was in-frame inserted
into vector pGEX-6P-1 (Amersham Pharmacia Biotech). E. coli cells
were cultured in Luria broth containing 50 lg/ml ampicillin overnight
at 37 C. Cells were induced with 400 lM IPTG for 2 h at 37 C and
GST-CHASMwas isolated using glutathione-Sepharose 4B beads. For
in situ experiments, the CHASM recombinant protein was cleaved by
treatment with PreScission ProteaseTM as described by the manufac-
turer (Amersham Pharmacia Biotech). A phosphorylation site mutant
CHASM protein (S301A) was generated with the QuickChange Site
Directed mutagenesis kit (Stratagene, La Jolla, CA). The CHASM
S301A mutant protein was expressed and puriﬁed as described above.
2.5. In vitro phosphorylation of recombinant
CHASM by PKG, PKA, CaMKII, MAPK, rMYPT1K, and MLCK-
Phosphorylation of CHASM (0.55 mg/ml) was performed at 25 C in
25 mM HEPES, pH 7.2, 1 mM MgCl2, and 0.1 mM DTT, with 0.2
mM [c-32P]ATP and 30 ng/ml of either PKG-Ia, PKA catalytic sub-
unit, activated p42MAPK, CaMKII, rMYPT1K or MLCK. MAPK was
activated by phosphorylation with recombinant S218D/S222D MEK1
as previously described [27]. Assays with MLCK and CaMKII were
carried out in a buﬀer that also contained 10 lM CaCl2 and 2.5 lM
calmodulin. Reactions were terminated at the indicated time points
by addition of Laemmli sample buﬀer. Proteins were resolved by
SDS–PAGE and phosphorylated CHASM was visualized by
autoradiography.
2.6. Muscle tension measurements
For in situ force measurements, sheets of longitudinal muscle were
peeled and cut into small strips (3 mm 250 lM). Muscle strips were
attached to a force transducer (SensorOne AE801, Sausalito, CA) in a
‘‘bubble’’ chamber and stretched to 1.3 times resting length. Muscle
strips were permeabilized by incubation for 30 min with 50 lM b-escin
in an intracellular solution containing 1 mM EGTA and no added
Ca2þ (G1) with 10 lM A23187 added for the ﬁnal 10 min to deplete
intracellular calcium stores. All experiments were carried out at room
temperature.
2.7. Actin co-sedimentation assay
An actin co-sedimentation assay was performed to investigate the
ability of CHASM to bind actin. Precission ProteaseTM-cleaved, re-
combinant CHASM protein (1 lM) was incubated with F-actin (9 lM)
in F-actin buﬀer (25mM Tris–HCl, pH 7.5, 130 mM KCl, 0.1 mM
CaCl2, 8.6 mM MgCl2, 1 mM ATP, and 1 mM dithiothreitol) for 1 h
at 25 C. In some experiments, tropomyosin (1 lM) was added as a
postive-control for actin binding. After the incubation, the protein
mixtures were ultracentrifuged at 150,000· g for 1 h at 4 C. The su-
pernatant was separated from the pellet and the proteins present in
each fraction were resolved by SDS–PAGE with Coomassie or silver
staining.3. Results
3.1. Identiﬁcation of a novel smooth muscle protein
phosphorylated in response to 8-Br-cGMP administration
In order to identify possible candidate proteins that con-
tribute to cyclic nucleotide-induced Ca2þ desensitization, we
permeabilized sheets of rabbit ileum smooth muscle and
treated them with either vehicle (water) or 8-Br-cGMP, a
non-hydrolyzable analogue of cGMP, in the presence of
exogenously added [c-32P] ATP. Addition of [c-32P] ATP with
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ensured that only those phosphorylation events directly med-
iated by PKG would be identiﬁed, thereby greatly reducing the
complexity of phosphoproteins that one would normally ob-
serve following steady state 32P-labelling of intact muscles.
Acute 8-Br-cGMP-stimulation of ileum smooth muscle was
associated with an increase in phosphorylation of a number of
proteins (Fig. 1A). Proteins exhibiting an increase in 32P in-
corporation (phosphorylation) in response to 8-Br-cGMP were
identiﬁed in 2D gels by mass spectrometry. Consistent with
previously published results, we found increased phosphory-
lation of telokin [16] (Fig. 1A, labeled 5), and the 20 kDa heat
shock-related protein, HSP20 [30–32] (labeled 2), in response
to 8-Br-cGMP stimulation (mass spectrometry sequence data
not shown). An increase in phosphorylation in response to
8-Br-cGMP stimulation was also detected for actin depoly-
merizing factor (labeled 4). Phosphorylation of a ubiquitin
conjugating enzyme (labeled 3) was detected. The roles of these
proteins in cyclic nucleotide-dependent smooth muscle relax-
ation remain undeﬁned. Some proteins that demonstrated
increases in phosphorylation with 8-Br-cGMP-induced relax-
ation were not identiﬁed due to insuﬃcient protein quantity.
Most interestingly, we observed a fourteen fold increase in
the phosphorylation of an acidic protein of approximately 60
kDa (Fig. 1A, labeled 7) when the vehicle treated control was
compared with 8-Br-cGMP stimulation, 1.0 0.3 versus
14.2 1.4 (mean S.E.M. for n ¼ 4 separate experiments).
Two peptides obtained from the trypsin digestion of this
protein were sequenced by nanospray mass spectrometry andFig. 1. Identiﬁcation of CHASM as a novel target for cGMP-dependent prot
rabbit ileum smooth muscle showing acute phosphorylation events. Sheets o
tracted with pCa 6.3. Following a 5 min incubation with [c-32P] ATP, vehicl
were rapidly frozen in liquid nitrogen and processed for 2D-gel electropho
trometry: (1a,b,c) HSP27, (2a,b) p20, (3) ubiquitin conjugating enzyme, (4)
labeled (6) was below detection limits. Autoradiograms are representatives o
from protein 7, sequenced by nanospray tandem mass spectrometry, using taligned within the sequence of a RIKEN cDNA putative gene
product (Fig. 1B). The sequence of the RIKEN putative gene
product revealed the presence of a calponin homology (CH)
domain at its carboxyl terminus (Fig. 2). We have designated
this protein CHASM for Calponin Homology-Associated
Smooth Muscle protein. The next highest scoring sequence was
smoothelin (expectation score of 0.18), a smooth muscle-
speciﬁc protein also characterized by the presence of a
CH-domain at its carboxyl terminus [33].
A FASTA search of the public databases with the full length
CHASM sequence showed a high degree of similarity in the C
terminus (residues 347–451) with the CH2 domains found in
the smoothelins (Fig. 2). Smoothelin proteins are found ex-
clusively in diﬀerentiated smooth muscle tissue [34]. Although
the entire N-terminal domain of CHASM shares minimal
similarity with the smoothelins, close inspection of the primary
sequence alignment reveals a number of additional amino ac-
ids that are conserved in all four proteins (Fig. 2). Many of
these residues are basic or acidic amino acids that are dis-
tributed throughout the entire protein sequence. Notably, and
in contrast to the smoothelins, the CHASM protein possesses a
single, consensus site for phosphorylation by cyclic nucleotide-
dependent protein kinases (Ser 301) (Fig. 2).
3.2. CHASM is phosphorylated by cyclic nucleotide-dependent
kinases
Based on the amino acid sequence of CHASM, a single
consensus phosphorylation sequence for PKG/PKA was pre-
dicted by PhosphoBase analysis [35]. Accordingly, PKG andein kinase. (A) Autoradiograms of control and 8-Br-cGMP-stimulated
f a-toxin permeabilized smooth muscle were washed in G1 and con-
e (water) or 50 lM 8-Br-cGMP was added. After 5 min, muscle sheets
resis. Phosphorylated proteins were identiﬁed by tandem mass spec-
actin depolymerizing factor (5) telokin, and (7) CHASM. The protein
f at least 6 independent experiments. (B) Alignment of tryptic peptides
he FASTS algorithm.
Fig. 2. Sequence alignment of mouse CHASM with the smoothelin isoforms. The sequence analysis of CHASM (NM_024230), smoothelin S2
(AAF25580), and smoothelin L2 (AAF01480) was completed using the ClustalW multiple sequence alignment program (www.ebi.ac.uk http://
www.ebi.ac.uk). The locations of the calponin homology domain, the single PKG phosphorylation site, the tropomyosin binding domain, and the
actin binding domains are indicated. Amino acid residues identical in all proteins are indicated with (*), conserved substitutions are denoted by (:),
and semi-conserved substitutions are denoted by (.).
210 M.A. Borman et al. / FEBS Letters 573 (2004) 207–213PKA phosphorylated recombinant CHASM equally well in
vitro (Fig. 3A). CHASM was phosphorylated to a stoichiom-
etry of 1 mol of phosphate/mol of protein and phosphoamino
acid analysis indicated phosphorylation of serine alone
(Fig. 3C). Mutation of Ser 301 to Ala completely abolished the
in vitro phosphorylation of CHASM by PKG (Fig. 3B), con-
ﬁrming PKG phosphorylation at a single residue. These ﬁnd-
ings suggest that cGMP- and cAMP-activated kinase(s) could
mediate CHASM phosphorylation in smooth muscle. Al-
though Ser 301 is also a predicted Ca2þ/calmodulin-dependent
kinase II (CaMKII) consensus sequence, CHASM was a poor
substrate for CaMKII (Fig. 3A). Similarly, CHASM was not
signiﬁcantly phosphorylated by mitogen-activated protein ki-
nase (MAPK), recombinant myosin phosphatase-associated
kinase (rMYPT1K) or myosin light chain kinase (MLCK),
suggesting that CHASM is phosphorylated only by cyclic
nucleotide-dependent protein kinases and that no signiﬁcant
phosphorylation occurs in the presence of Ca2þ-dependent
kinases in vitro.3.3. CHASM elicits Ca2þ desensitization in b-escin
permeabilized smooth muscle strips
Next, we examined the physiological eﬀects of CHASM on
b-escin permeabilized strips of rabbit ileum longitudinal
smooth muscle. In these preparations, it is possible to strictlycontrol [Ca2þ]i thereby providing a method of evaluating the
eﬀects of recombinant proteins in the absence of changes in
calcium levels [14,16]. Contraction was induced by incubation
in submaximal calcium prior to the addition of recombinant
CHASM. CHASM relaxed submaximally contracted smooth
muscle at constant [Ca2þ]i in a concentration-dependent
manner (Fig. 4A). A maximum relaxation of 42.5 4.3%
(n ¼ 5) was observed with 20 lM CHASM (Fig. 4B). A buﬀer
control did not elicit any signiﬁcant relaxation in the per-
meabilized muscle (data not presented).3.4. Actin co-sedimentation assay
We examined the ability of full-length CHASM protein to
co-sediment with actin in vitro. The CHASM protein did not
co-sediment with actin (Fig. 5). Binding studies using actin (3
lM) with increasing amounts of CHASM (1, 3, 6, and 9 lM)
were also unable to reveal any co-sedimentation of CHASM
with actin (results not shown). While tropomyosin was found
to be associated with actin following the co-sedimentation
procedure, the addition of tropomyosin did not enable
CHASM co-sedimentation with actin. These results suggest
that the single CH-domain present in CHASM is insuﬃcient
for actin binding. Outside of the single CH-domain, CHASM
does not contain any additional actin-binding or tropomyosin-
binding domains.
Fig. 3. Analysis of CHASM phosphorylation. (A) Autoradiograms
showing the time course of phosphorylation of recombinant CHASM
by the indicated protein kinases. (B) Autoradiograms showing the time
course of phosphorylation of recombinant Ser301!Ala CHASM. (C)
Stoichiometry of phosphorylation by PKG of wild-type (d) and
S301A (m) CHASM proteins. Inset: phospho-amino acid analysis of
PKG-phosphorylated CHASM.
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The function of the smoothelin family of proteins is un-
known; however, the smoothelins are found only in contractile
smooth muscle cells and are often used as markers for the
diﬀerentiated phenotype of smooth muscle [33]. Two isoforms
of smoothelin have been identiﬁed: a 59 kDa isoform
(smoothelin A) that is expressed in visceral smooth muscle
such as intestine [33] and a 100 kDa isoform (smoothelin B)
that is expressed in vascular smooth muscle [34]. More re-
cently, Leonhart and colleagues [36] have deﬁned two alternate
splice variants that contain spectrin family similarity. In thisreport, we present an additional member of the smoothelin
family of proteins. The protein, termed CHASM, is unique
among the smoothelin family in that it possesses a site for
phosphorylation by cyclic nucleotide kinases.
In the present study, protein phosphorylation during cGMP-
induced relaxation in smooth muscle was evaluated using a
combination of real-time proteomics and smooth muscle
physiology. Increased phosphorylation of the CHASM protein
was identiﬁed as an early event in cGMP-induced smooth
muscle relaxation. Both smoothelin isoforms (and CHASM)
are characterized by the presence of a calponin homology
domain at their carboxyl-termini. There is no evidence that the
smoothelins play a role in smooth muscle Ca2þ desensitization
or are phosphorylated in response to 8-Br-cGMP stimulation.
Notably, there are no predicted PKG phosphorylation sites
within the smoothelin sequences (based on a PhosphoBase
analysis) [35]. Furthermore, the amino terminal domain of
CHASM (residues 1–346), which contains the predicted
phosphorylation site, is quite divergent from the smoothelins.
Calponin is an actin-binding protein that is almost exclu-
sively expressed in smooth muscle [37]. The calponin homol-
ogy domains were identiﬁed in this protein as regions that
contributed to its actin binding and have since been identiﬁed
in a number of actin-binding proteins and signaling molecules
[38]. Calponin and other CH-domain containing proteins may
regulate smooth muscle contractility via the thin ﬁlament
regulatory system [37]. Upon association with actin ﬁlaments,
calponin inhibits the actin-activated Mg2þ-ATPase activity of
myosin [39]. We have demonstrated that CHASM is unable to
associate with actin ﬁlaments in vitro. Previous reports [40]
have demonstrated that the single CH-domain of calponin is
neither necessary nor suﬃcient for its actin binding [40] and
support our ﬁnding that the single CH-domain found in
CHASM is not suﬃcient for actin binding. It has been sug-
gested that two CH-domains in tandem are required for actin-
binding (reviewed in [41]). The smoothelins possess novel
actin binding domains that are responsible for association with
actin containing ﬁlaments [36]. The large vascular speciﬁc
smoothelin isoform contains two actin binding domains,
whereas the small visceral speciﬁc isoform contains only one
actin binding domain (Fig. 2). Both smoothelin isoforms also
contain a tropomyosin binding domain [36]. CHASM lacks the
novel actin binding domains found in the smoothelin proteins.
Importantly, we have found that the addition of the full length
CHASM protein to microcystin-treated smooth muscles (to
block dephosphorylation of myosin by endogenous myosin
phosphatase activity) did not cause relaxation (preliminary
data not presented). This ﬁnding supports a hypothesis that
CHASM possesses a regulatory role in the signaling process,
potentially through modulation of myosin phosphatase activ-
ity, rather than a disruption of myosin ATPase activity and
cross-bridge cycling.
The NO-cGMP pathway contributes to relaxation by de-
creasing the Ca2þ sensitivity of cross-bridge phosphorylation
[42]. The evidence suggests that this phenomenon is modulated
through myosin phosphatase regulation [16,17,42]. The asso-
ciation between increases in CHASM phosphorylation and the
cGMP-dependent inhibition of contraction suggests that
CHASM may be important in modulating this process.
CHASM’s ability to elicit relaxation without a change in
[Ca2þ]i indicates that CHASM functions by activating the
Ca2þ desensitization pathway. Based on the signiﬁcant in-
Fig. 4. CHASM-induced smooth muscle calcium desensitization. (A) b-escin permeabilized rabbit ileum smooth muscle strips were contracted with
submaximal calcium (pCa 6.3), and at the plateau of contraction wild-type, Precission ProteaseTM-cleaved CHASM was added. (B) The concen-
tration-dependence of relaxation induced by CHASM. Percent relaxations are calculated from the plateau of the pCa 6.3 contraction. Data are
representatives of at least n ¼ 4 experiments.
Fig. 5. Co-sedimentation assay of CHASM with F-actin and tropomyosin. F-actin was sedimented by ultracentrifugation and associated proteins
were identiﬁed by SDS–polyacrylamide electrophoresis: S, ultracentrifuged supernatant; P, ultracentrifuged precipitate. Precission ProteaseTM-
cleaved CHASM (1 lM) was incubated with (+) or without ()) F-actin (9 lM) and tropomyosin (1 lM) in F-actin buﬀer for co-sedimentation assay.
212 M.A. Borman et al. / FEBS Letters 573 (2004) 207–213crease in CHASM phosphorylation observed during the early
stages of smooth muscle relaxation, a role for cGMP-induced
CHASM phosphorylation seems likely. Further evaluation is
necessary to elucidate the precise mechanism of CHASM
regulation and the role of phosphorylation therein.
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